linjc16/ctgov huggingface dataset:
Allergy Testing of Soldiers Prepared for International Mission

Study Overview
=================
Brief Summary
-----------------
The goal of this prospective mono centric study is to identify relevant commercially available allergen extracts for allergy testing in soldiers prepared for international mission. Participants will receive a skin prick test with the skin prick automated test device including 22 allergens and 2 controls on both forearms.

Official Title
-----------------
Validation of the Benefit of Allergy Testing of Soldiers Prepared for International Mission With Specific Allergen Panels

Conditions
-----------------
Adult Military Personnel

Intervention / Treatment
-----------------
* Device: Skin Prick Automated Test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult military personnel (18-65y) will be included. Soldiers with and without previous exposure to allergens in the regions of interest will be included. Soldiers who are performing desk tasks and not selected for international missions will serve as controls. Exclusion Criteria: Skin pathology like chronic or exuberant urticaria, dermographism, chronic dermatitis that needs daily treatment Use of antihistaminic medication < 7 days before the start of the study Use of tricyclic antidepressants (antihistamine activity) < 7 days before the start of the study Use of topical corticoids on the forearm < 7 days before the start of the study Use of Omalizumab < 6 months before the start of the study Pregnancy: there is a remote possibility of inducing a systemic allergic reaction that could induce uterine contractions or necessitate the use of epinephrine (thought to cause constriction of the umbilical artery).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Skin Prick Automated Test<br> | Device: Skin Prick Automated Test<br>* A skin prick automated test will be performed in each participant.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Allergens with positive skin reaction | Positive skin reactions of top ranked allergens required to identify 95% of sensitised individuals | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self-reported allergic diseases | Percentage of soldiers with self-reported allergic diseases derived from questionnaire | baseline | 
| Work Performance & Activity Impairment | Total score of Work Performance & Activity Impairment questionnaire, 0-100%, higher score means worse outcome | baseline |
Assessment of the Effect of Non-surgical Periodontal Treatment on Endothelial Function- a Prospective Study

Study Overview
=================
Brief Summary
-----------------
An association between periodontitis and endothelial dysfunction has been reported, suggesting that periodontitis presents an inflammatory burden to the cardiovascular system, that might lead to AVD. The study aims aim to assess whether non-surgical periodontal therapy enhances endothelial function in periodontitis patients using a non-invasive diagnostic device to assess endothelial function through PWA and the assessment of levels of salivary Endothelin-1, in a population of people in the UAE.

Official Title
-----------------
Assessment of the Effect of Non-surgical Periodontal Treatment on Endothelial Function- a Prospective Study

Conditions
-----------------
Endothelial Dysfunction, Periodontal Diseases

Intervention / Treatment
-----------------
* Diagnostic Test: Assessment of pulse wave amplitude (PWA)
* Diagnostic Test: Salivary Nitric Oxide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Group 1: periodontally healthy subjects. Group 2: patients with periodontitis stage III or IV and grades A,B or C. Exclusion Criteria: Medical conditions: Diabetes,pregnancy,obesity,renal disease,patients with cardiovascular diseases including hypertension,recent myocardial infarction or unstable angina (within 3 months),congestive heart failure,valvular heart disease Heavy smokers(>10 cigarettes per day), Regular administration of drugs resulting in gingival hyperplasia,root planning in the past 6 months Regular administration of drugs resulting in gingival hyperplasia (such as cyclosporine and phenytoin) Recent antibiotic use (in the past 3 months) Non-surgical periodontal therapy in the past 6 monthsp

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Test<br>Periodontitis patients | Diagnostic Test: Assessment of pulse wave amplitude (PWA)<br>* Assessment of pulse wave amplitude (PWA) through peripheral arterial tonometry (PAT) using the device EndoPAT (Itamar Medical)<br>Diagnostic Test: Salivary Nitric Oxide<br>* assessment the levels of salivary Nitric Oxide using a Nitric Oxide colorimetric detection kit,<br>|
| Control<br>Periodontally healthy patients | Diagnostic Test: Assessment of pulse wave amplitude (PWA)<br>* Assessment of pulse wave amplitude (PWA) through peripheral arterial tonometry (PAT) using the device EndoPAT (Itamar Medical)<br>Diagnostic Test: Salivary Nitric Oxide<br>* assessment the levels of salivary Nitric Oxide using a Nitric Oxide colorimetric detection kit,<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pulse wave amplitude |  | 2 months |
Changes in the Blood-brain Barrier During Maintenance ECT in Formerly Depressed Patients

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to examine the effect of electroconvulsive therapy (ECT) on the blood-brain barrier (BBB) in patients who had suffered from depression. We will study the BBB with dynamic contrast enhanced (DCE) MRI before and after treatment with a single ECT in patients currently undergoing ECT. The study is an observational (naturalistic) longitudinal study.

Detailed Description
-----------------
Primary hypothesis The BBB permeability to Gadovist (measured as Ki) temporarily increases in the right and left hippocampus (HC) after a single ECT. Secondary hypothesises The volume of the right and left HC increases after a single ECT and the volume increase is positively correlated with the BBB permeability A larger post-ECT increase in systolic blood pressure correlates with a larger increase in BBB permeability in the right and left HC. A larger increase in serum S100-B compared to baseline values is correlated with increased BBB permeability in the right and left HC.

Official Title
-----------------
Changes in the Blood-brain Barrier During Maintenance ECT in Formerly Depressed Patients

Conditions
-----------------
Depression

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - We will include patients (age 18-75) currently treated with a series of ECT or maintenance ECT referred to the treatment due to moderate to severe depression according to ICD-10. Exclusion Criteria: Schizophrenia Psychotic symptoms Any substance use (other than cigarette smoking and alcohol consumption within the recommendations of the Danish National Health Authority) within the last 3 months Risk of suicide making transport or participation in the study hazardous Claustrophobia or severe restlessness Contraindications to DCE-MRI (e.g., metallic implants, increased body temperature, reduced kidney function (estimated Global Filtration Rate (eGFR) of <40 ml/min/1.73 m2), pregnancy) Somatic illness potentially confounding results (e.g., any central nervous system diseases or cancers) Lack of consent to being informed of potential medically important findings on MRI or blood tests

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Permeability | Change in permeability measured as Ki in the units of ml/100g/min in the right and left hippocampus | Permeability is measured before a single ECT and 0-8 hours after a single ECT |
Clinical Trial to Evaluate the Safety and Effectiveness of a Canaloplasty Device in Subjects With Open-Angle Glaucoma

Study Overview
=================
Brief Summary
-----------------
Clinical Trial to Evaluate the Safety and Effectiveness of a Canaloplasty Device in Subjects with Open-Angle Glaucoma

Official Title
-----------------
Clinical Trial to Evaluate the Safety and Effectiveness of a Canaloplasty Device in Subjects With Open-Angle Glaucoma

Conditions
-----------------
POAG

Intervention / Treatment
-----------------
* Device: Canaloplasty Device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects qualifying for cataract surgery Subjects with diagnosis of open-angle glaucoma in at least one eye with unmedicated IOP of 22-34 mmHg. Exclusion Criteria: 1. Patients who cannot be washed-out of IOP-lowering medications.

Ages Eligible for Study
-----------------
Minimum Age: 22 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment with a Canaloplasty Device<br>Canaloplasty Device | Device: Canaloplasty Device<br>* Canaloplasty<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IOP change | proportion of treated eyes with > 20% change in unmedicated IOP | Month6 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IOP | Change in IOP | Months 6 and 12 | 
| IOP meds | Change in number of IOP lowering medications | Month 6 and 12 |
Correlation Between Popliteal Vein Compliance and Venous Clinical Severity Score

Study Overview
=================
Brief Summary
-----------------
When the liquid flow increases, the luminal caliber's stretching amplitude decreases, leading to a higher hydraulic pressure according to Poiseuille's law. In this study, investigators measured the caliber change of the popliteal vein under a rated pressure gradient and evaluated the relationship between popliteal vein compliance and venous clinical severity score (VCSS).

Official Title
-----------------
Correlation Between Popliteal Vein Compliance and Venous Clinical Severity Score

Conditions
-----------------
Chronic Venous Disease (CVD), Vein Compliance, Venous Clinical Severity Score (VCSS)

Intervention / Treatment
-----------------
* Other: Popliteal Vein Compliance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: C1 to C6 disease using the CEAP (clinical, etiologic, anatomic, pathophysiologic) classification. Exclusion Criteria: acute or chronic thrombosis of deep veins, previously received intravenous surgery or injection sclerotherapy, ankle brachial index<0.90, and concomitant cardiovascular, pulmonary, renal, or metabolic diseases.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| control group<br> | Other: Popliteal Vein Compliance<br>* Compliance of the popliteal vein is calculated as the distensibility, with the ratio of functional caliber/native caliber/cuff pressure value ( mmHg-1 ).<br>|
| experimental group<br> | Other: Popliteal Vein Compliance<br>* Compliance of the popliteal vein is calculated as the distensibility, with the ratio of functional caliber/native caliber/cuff pressure value ( mmHg-1 ).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compliance of the popliteal vein | Compliance of the popliteal vein is calculated as the distensibility, with the ratio of functional caliber/native caliber/cuff pressure value | May 2023 to October 2023 |
Multiple Disseminated Hydatidosis With Rare Locations

Study Overview
=================
Brief Summary
-----------------
Hydatid disease is an anthropozoonosis due to the development of the larval form of Echinococcus granulosus in the human body, which constitutes a 'dead-end' host. It's a common parasitosis in North African countries and constitutes a public health problem in Morocco. The liver and lung are the most affected while the mediastinum, pancreas and pelvis are rarely affected. We report the case of a 40-year-old patient operated 15 years ago for cerebral and cervical hydatid cysts and who was hospitalized for generalized mucocutaneous jaundice. On exploration, we discover the presence of disseminated abdominal hydatidosis with association of 3 rare locations: mediastinal, pancreatic and pelvic. Indirect diagnostic tests were positive: indirect hemagglutination (IHA) and Elisa. The Western blot test also showed the presence of specific bands, thus making it possible to retain the diagnosis of hydatidosis. The hydatid cyst with mediastinal, pancreatic and pelvic location is rare and their association is very exceptional. It is essential to evoke the hydatid origin of any cystic lesion in a patient staying in an endemic area.

Official Title
-----------------
Multiple Disseminated Hydatidosis With Rare Locations: Mediastinal, Pancreatic and Pelvic: Case Report

Conditions
-----------------
Echinococcus Infections

Intervention / Treatment
-----------------
* Procedure: duct diversion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: none Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 44 Years
Maximum Age: 44 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: duct diversion|the patient benefited from a diversion of the bile ducts complicated by ruptured cysts with anaphylactic shock|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| THE PATIENT DIED due to probably anaphylactic shock | the patient probably had the rupture of cysts during the surgical procedure with anaphylactic shock as a complication | 1 mounth | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
echinococcus, serology, multiple locations
Anti-Müllerian Hormone and Embryo Aneuploidy

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to determine is there an association between the rates of aneuploidy and the different ranges of serum Antimullerian hormone (AMH) levels. Retrospective, single-centre study of patients undergoing IVF and preimplantation genetic testing with aneuploidy at the blastocyst stage between January 2018 and December 2022.

Official Title
-----------------
Serum Anti-Müllerian Hormone Levels and Its Association With Aneuploidy Rates in Human Blastocysts

Conditions
-----------------
Infertility, Aneuploidy

Intervention / Treatment
-----------------
* Other: preimplantation genetic test for aneuploidies (PGT-a)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All started cycles planned to be followed by preimplantation genetic testing for aneuploidies (PGT-A). PGT-A is proposed to the couples for the following reasons: advanced maternal age, recurrent miscarriage, repeated implantation failure or severe male infertility factor; it is also offered to all patients with a good prognosis who desired information regarding the ploidy status of their embryos. Exclusion Criteria: Data from oocyte donation cycles
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| AMH < 0.5 ng/ml<br> | Other: preimplantation genetic test for aneuploidies (PGT-a)<br>* preimplantation genetic test for embryo aneuploidies after IVF<br>|
| AMH 0.5-0.99 ng/ml<br> | Other: preimplantation genetic test for aneuploidies (PGT-a)<br>* preimplantation genetic test for embryo aneuploidies after IVF<br>|
| AMH 1.0-1.49 ng/ml<br> | Other: preimplantation genetic test for aneuploidies (PGT-a)<br>* preimplantation genetic test for embryo aneuploidies after IVF<br>|
| AMH 1.5-1.99 ng/ml<br> | Other: preimplantation genetic test for aneuploidies (PGT-a)<br>* preimplantation genetic test for embryo aneuploidies after IVF<br>|
| AMH 2.0-4.99 ng/ml<br> | Other: preimplantation genetic test for aneuploidies (PGT-a)<br>* preimplantation genetic test for embryo aneuploidies after IVF<br>|
| AMH > 5.0 ng/ml<br> | Other: preimplantation genetic test for aneuploidies (PGT-a)<br>* preimplantation genetic test for embryo aneuploidies after IVF<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aneuplody rate |  | 4 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical pregnancy rate |  | 4 years | 
| Miscarriage rate |  | 4 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AMH, IVF, Aneuploidy, PGT-a, anti-mullerian hormone, oocyte quality
Role of B Mode and Color Doppler Sonography in Differentiation Between Pleural Neoplasm and Inflammatory Pleural Thickening in Correlation With CT Findings

Study Overview
=================
Brief Summary
-----------------
pleura is a serous membrane, it consist of parietal pleura and visceral pleura. pleural thickening is any form of thickening involving the pleura more than 3 mm. there is malignant thickening : methoselioma, metastasis and non malignant thickening. trans thoracic USn is a reliable , safe and gold standard for studying pleura.

Official Title
-----------------
Role of B Mode and Color Doppler Sonography in Differentiation Between Pleural Neoplasm and Inflammatory Pleural Thickening in Correlation With CT Findings

Conditions
-----------------
Pleural Thickening

Intervention / Treatment
-----------------
* Diagnostic Test: biopsy under sonographic gidance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients diagnosed as having pleural thickening with or without pleural effusion. Exclusion Criteria: Emphysema or contraindication to pleural biopsy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: pleural disease<br> | Diagnostic Test: biopsy under sonographic gidance<br>* pleural biopsy under sonographic guidance<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sensitivity of sonography in pleural thickening in comparison to CT and histopathology | sensitivity of sonography in cases of pleural thickening in comparison to CT findings and histopathology | one year |
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

Study Overview
=================
Brief Summary
-----------------
This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.

Detailed Description
-----------------
This study will consist of patients who have completed their participation in a previous plaque psoriasis study of ESK-001. Each patient will be assigned to receive ESK-001 at one of two open-label dose levels. Patients have the option to remain on study until ESK-001 is commercially available.

Official Title
-----------------
A Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Patients With Plaque Psoriasis

Conditions
-----------------
Plaque Psoriasis

Intervention / Treatment
-----------------
* Drug: ESK-001


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must have completed a prior ESK-001 study Men and Women must use highly effective methods of contraception for the entirety of the study Exclusion Criteria: Pregnancy Received a prohibited concomitant medication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ESK-001 Dose Level 1<br>ESK-001 administered as an oral tablet | Drug: ESK-001<br>* Oral tablet<br>|
| Experimental: ESK-001 Dose Level 2<br>ESK-001 administered as an oral tablet | Drug: ESK-001<br>* Oral tablet<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the safety and tolerability of long-term ESK-001 treatment | Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) | Approximately 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the long-term efficacy of ESK-001 | Change from baseline in Psoriasis Area and Severity Index (PASI) over time | Approximately 3 years | 
| To assess the change in quality of life (QoL) with long-term ESK-001 administration | Change from baseline in Dermatology Life Quality Index (DLQI) over time | Approximately 3 years | 
| To assess the pharmacokinetics (PK) of ESK-001 (ctrough) | Plasma concentrations and PK parameters including steady-state trough observed plasma concentration (Ctrough) for ESK-001 | 2 years |